Technical Insights on Diagnostic Substances Stocks -- Atossa Genetics, AMAG Pharma, IDEXX Laboratories, and Quidel

Monday, October 23, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, October 23, 2017 /PRNewswire/ --

If you want a Stock Review on ATOS, AMAG, IDXX, or QDEL then come over

to and sign up for your free customized report. On Friday, benchmark US indices were in bullish colors as the NASDAQ Composite closed the trading session up 0.36%; the Dow Jones Industrial Average edged 0.71%
higher; and the S&P 500 was up 0.51%. US markets made broad based gains with eight out of nine sectors finishing the day in green. Pre-market today, reviews these four Diagnostic Substances stocks: Atossa Genetics Inc. (NASDAQ: ATOS), AMAG Pharmaceuticals Inc. (NASDAQ: AMAG), IDEXX Laboratories Inc. (NASDAQ: IDXX), and Quidel Corp. (NASDAQ: QDEL). Access's free research reports for this morning's stocks line-up at:

Atossa Genetics 

Seattle, Washington headquartered Atossa Genetics Inc.'s stock finished Friday's session 3.60% lower at $0.48. A total volume of 382,005 shares was traded. The Company's shares have advanced 23.23% over the previous three months. The stock is trading below its 50-day moving average by 0.73%. Furthermore, shares of Atossa Genetics, which focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the US, have a Relative Strength Index (RSI) of 47.52. Free research report on ATOS is available at:

AMAG Pharmaceuticals 

Shares in Waltham, Massachusetts headquartered AMAG Pharmaceuticals Inc. ended at $15.60, down 2.80% from the last trading session. The stock recorded a trading volume of 1.76 million shares, which was above its three months average volume of 827.72 thousand shares. The stock is trading below its 50-day moving average by 13.46%. Moreover, shares of AMAG Pharma, which manufactures, develops, and commercializes therapeutics for women's health, anemia management, and cancer supportive care in the US, have an RSI of 30.36. The complimentary research report on AMAG can be downloaded at:

IDEXX Laboratories 

Westbrook, Maine headquartered IDEXX Laboratories Inc.'s stock ended last Friday's session 1.94% higher at $164.71 with a total trading volume of 409,729 shares. The Company's shares have advanced 46.98% in the last twelve months and 40.45% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 5.41% and 7.20%, respectively. Additionally, shares of IDEXX Labs, which together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide, have an RSI of 63.20. Visit us today and access our complete research report on IDXX at:


On Friday, shares in San Diego, California headquartered Quidel Corp. recorded a trading volume of 273,678 shares. The stock finished the day 0.43% lower at $41.77. The Company's shares have advanced 10.44% in the previous three months, 96.56% over the last twelve months, and 95.00% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 8.42% and 49.34%, respectively. Furthermore, shares of Quidel, which develops, manufactures, and markets diagnostic testing solutions for applications primarily in infectious diseases, POC women's and general health, and gastrointestinal diseases, have an RSI of 53.01. Get free access to your research report on QDEL at:


Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store